Astrana Health (ASTH) Stock Forecast & Price Target

Compare

255 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ASTH Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Astrana

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ASTH Stock 12 Month Forecast

Average Price Target

$41.00

▲(39.79% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Astrana Health in the last 3 months. The average price target is $41.00 with a high forecast of $50.00 and a low forecast of $33.00. The average price target represents a 39.79% change from the last price of $29.33.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","39":"$39","58":"$58","29.5":"$29.5","48.5":"$48.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,29.5,39,48.5,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.57,23.756923076923076,25.943846153846152,28.130769230769232,30.317692307692308,32.504615384615384,34.691538461538464,36.878461538461536,39.065384615384616,41.252307692307696,43.43923076923077,45.62615384615385,47.81307692307692,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.57,23.064615384615387,24.55923076923077,26.053846153846155,27.548461538461538,29.043076923076924,30.53769230769231,32.0323076923077,33.526923076923076,35.02153846153846,36.51615384615385,38.01076923076923,39.505384615384614,{"y":41,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.57,22.44923076923077,23.32846153846154,24.20769230769231,25.086923076923078,25.966153846153848,26.845384615384617,27.724615384615383,28.603846153846156,29.483076923076922,30.362307692307695,31.24153846153846,32.12076923076923,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.73,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.84,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.53,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.81,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.53,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.87,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.38,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.57,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$41.00

Lowest Price Target$33.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rosa Clinessa

TR | OpenAI - 4o

$31→$33

Buy

12.51%

Upside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Jailendra Singh

Truist Financial

―

Buy

―

Reiterated

08/12/25

Truist Financial Sticks to Their Buy Rating for Astrana Health (ASTH)

David Larsen

BTIG

$50

Buy

70.47%

Upside

Reiterated

08/10/25

Astrana Health: Strong Financial Performance and Strategic Growth Drive Buy RatingWe expect ASTH to get below 2.5x over the next 12-18 months and ultimately below 2x. Prospect should add at least ~$81M in EBITDA, with another ~$12-$15M in synergies from operational G&A improvements over time. and revenue growth seem high, and we like ASTH's control over the data and medical trend.

Joanna Gajuk

Bank of America Securities

―

Buy

―

Reiterated

08/08/25

Bank of America Securities Reaffirms Their Buy Rating on Astrana Health (ASTH)

Ryan Langston

TD Cowen

$40

Buy

36.38%

Upside

Reiterated

08/08/25

TD Cowen Remains a Buy on Astrana Health (ASTH)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

08/07/25

Astrana Health: Strong Performance and Promising Growth Prospects Drive Buy Rating

Jack Slevin

Jefferies

$44

Buy

50.02%

Upside

Reiterated

05/15/25

Analysts' Top Healthcare Picks: Astrana Health (ASTH), NexGel Inc (NXGL)

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Reiterated

05/12/25

Astrana Health (ASTH) Gets a Hold from KeyBanc

Andrew Mok CFA

Barclays

$36

Hold

22.74%

Upside

Reiterated

05/12/25

Analysts Offer Insights on Healthcare Companies: Astrana Health (NASDAQ: ASTH) and Amphastar Pharmaceuticals (NASDAQ: AMPH)

Brooks O'Neil

Lake Street

$70

Buy

138.66%

Upside

Reiterated

05/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioHarvest Sciences (NASDAQ: BHST), Astrana Health (NASDAQ: ASTH) and Joint (NASDAQ: JYNT)

Michael Craig Jones

Stifel Nicolaus

$56→$50

Buy

70.47%

Upside

Reiterated

02/28/25

Stifel Nicolaus Sticks to Their Buy Rating for Astrana Health (ASTH)

Michael Ha

Robert W. Baird

$86→$50

Buy

70.47%

Upside

Reiterated

02/28/25

Astrana Health price target lowered to $50 from $86 at BairdAstrana Health price target lowered to $50 from $86 at Baird

Tao Qiu

Macquarie

$41

Hold

39.79%

Upside

Initiated

12/16/24

Astrana Health initiated with a Neutral at MacquarieAstrana Health initiated with a Neutral at Macquarie

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rosa Clinessa

TR | OpenAI - 4o

$31→$33

Buy

12.51%

Upside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Jailendra Singh

Truist Financial

―

Buy

―

Reiterated

08/12/25

Truist Financial Sticks to Their Buy Rating for Astrana Health (ASTH)

David Larsen

BTIG

$50

Buy

70.47%

Upside

Reiterated

08/10/25

Joanna Gajuk

Bank of America Securities

―

Buy

―

Reiterated

08/08/25

Bank of America Securities Reaffirms Their Buy Rating on Astrana Health (ASTH)

Ryan Langston

TD Cowen

$40

Buy

36.38%

Upside

Reiterated

08/08/25

TD Cowen Remains a Buy on Astrana Health (ASTH)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

08/07/25

Astrana Health: Strong Performance and Promising Growth Prospects Drive Buy Rating

Jack Slevin

Jefferies

$44

Buy

50.02%

Upside

Reiterated

05/15/25

Analysts' Top Healthcare Picks: Astrana Health (ASTH), NexGel Inc (NXGL)

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Reiterated

05/12/25

Astrana Health (ASTH) Gets a Hold from KeyBanc

Andrew Mok CFA

Barclays

$36

Hold

22.74%

Upside

Reiterated

05/12/25

Analysts Offer Insights on Healthcare Companies: Astrana Health (NASDAQ: ASTH) and Amphastar Pharmaceuticals (NASDAQ: AMPH)

Brooks O'Neil

Lake Street

$70

Buy

138.66%

Upside

Reiterated

05/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioHarvest Sciences (NASDAQ: BHST), Astrana Health (NASDAQ: ASTH) and Joint (NASDAQ: JYNT)

Michael Craig Jones

Stifel Nicolaus

$56→$50

Buy

70.47%

Upside

Reiterated

02/28/25

Stifel Nicolaus Sticks to Their Buy Rating for Astrana Health (ASTH)

Michael Ha

Robert W. Baird

$86→$50

Buy

70.47%

Upside

Reiterated

02/28/25

Astrana Health price target lowered to $50 from $86 at BairdAstrana Health price target lowered to $50 from $86 at Baird

Tao Qiu

Macquarie

$41

Hold

39.79%

Upside

Initiated

12/16/24

Astrana Health initiated with a Neutral at MacquarieAstrana Health initiated with a Neutral at Macquarie

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Astrana Health

1 Month

xxx

Success Rate

6/9 ratings generated profit

Average Return

+4.46%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +4.46% per trade.

3 Months

xxx

Success Rate

7/9 ratings generated profit

Average Return

+1.79%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +1.79% per trade.

1 Year

David LarsenBTIG

Success Rate

5/9 ratings generated profit

Average Return

+7.64%

reiterated a buy rating 7 days ago

Copying David Larsen's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +7.64% per trade.

2 Years

xxx

Success Rate

3/10 ratings generated profit

Average Return

-9.04%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 30.00% of your transactions generating a profit, with an average return of -9.04% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ASTH Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ASTH has received 21 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ASTH average Analyst price target in the past 3 months is 41.00.

Each month's total comprises the sum of three months' worth of ratings.

ASTH Financial Forecast

ASTH Earnings Forecast

Next quarter’s earnings estimate for ASTH is $0.46 with a range of $0.42 to $0.50. The previous quarter’s EPS was $0.19. ASTH beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.26% of the time in the same period. In the last calendar year ASTH has Outperformed its overall industry.

ASTH Sales Forecast

Next quarter’s sales forecast for ASTH is $952.92M with a range of $944.34M to $966.70M. The previous quarter’s sales results were $654.81M. ASTH beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.42% of the time in the same period. In the last calendar year ASTH has Outperformed its overall industry.

ASTH Stock Forecast FAQ

What is ASTH’s average 12-month price target, according to analysts?

Based on analyst ratings, Astrana Health’s 12-month average price target is 41.00.

What is ASTH’s upside potential, based on the analysts’ average price target?

Astrana Health has 39.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ASTH a Buy, Sell or Hold?

Astrana Health has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Astrana Health’s price target?

The average price target for Astrana Health is 41.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $33.00. The average price target represents 39.79% Increase from the current price of $29.33.

What do analysts say about Astrana Health?

Astrana Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of ASTH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Astrana Health (ASTH) Stock Forecast & Price Target

ASTH Analyst Ratings

ASTH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Astrana Health

ASTH Analyst Recommendation Trends

ASTH Financial Forecast

ASTH Earnings Forecast

ASTH Sales Forecast

ASTH Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts